Preterm Birth Control Market to Affect Largely the Industry of Medical Device by 2025 - Integra LifeSciences, Panpac Medical Corp., Smiths Medical, Thomas Medical, Kangge Medical, Dr. Arabin, AMAG Pharmaceuticals

Overview of Preterm Birth Control Market

The research report titled ‘Preterm Birth Control Market’ provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability.

According to a new market research study titled ‘Preterm Birth Control Market - Global Analysis and Forecasts By Treatment Method, the global preterm birth control market is expected to reach US$ 1,809.0 Mn in 2025 from US$ 1,190.5 Mn in 2017. The market is estimated to grow with a CAGR of 4.9% from 2018-2025. The report highlights the trends prevalent in the global preterm birth control market and the factors driving the market along with those that act as deterrents to its growth.

Get Sample Report at https://www.theinsightpartners.com/buy/TIPMD00002026?OP+sK

Increasing Number of Preterm Births:
There has been a gradual increase in the number of preterm births from last few years. As per the World Health Organization (WHO), premature birth is a leading cause of death among the child below 5 years of age. It may be due to early induction of labor or caesarean birth. Multiple pregnancies, infections and chronic conditions such as diabetes and high blood pressure are others common causes of preterm births. As per the Centers for Disease Control and Prevention (CDC), reduction in preterm birth was observed from 2007-2014. In 2015, low birth weight and preterm birth accounted for about 17% of infant deaths. However, the number increased during 2016, with racial and ethnic differences. In the US, 1 of every 10 infants born was a preterm birth.

Initiatives towards Prevention of Preterm Birth:
A number of government and non-government organizations are engaged increasing awareness about preterm birth in various countries across the globe. Organizations such as CDC has implemented strategies to reduce preterm births. These strategies includes provision of healthcare services before and between pregnancies; determining population at the risk of preterm delivery and provide immediate treatment, discouraging deliveries before 39 weeks without a medical need; and preventing unintended pregnancies by waiting for at least 18 months between pregnancies.

Stringent Regulatory Framework:
Regulatory authorities such as Food & Drug Administration (FDA), European Medicine Agency (EMA) and others has consistently shown a tough stance towards pharmaceutical can biotechnology manufacturers. The market players must comply with the requirement and guidelines of FDA and other regulatory authorities and should constantly keep a check over time to time changes made in these guidelines. The manufacturers of pharmaceutical drugs and medical devices must abide by these regulations pertaining to current good manufacturing practices (cGMP) as well as good laboratory practices (GLP) in order to assure proper design, monitoring, and control of manufacturing processes and facilities. Furthermore, any deviations from the registered protocols, demands and requirements of these guidance leads to termination of the clinical trials undertaken by the pharmaceutical companies.

Additionally, FDA also requires strong safety monitoring and a strict dispensing plan to be followed by the manufacturer. Non-compliance by the manufacturers affects the sales of the products in the market and may lead to the recalls for marketed products due to instances recorded for deficit of the promises in the function and performance of the product or therapeutic may tarnish the company’s reputation risking its future growth. In case of clinical trials for development of therapeutics for preterm birth control, the FDA and other regulatory bodies have strict regulations due to which it is difficult for the manufacturers to pool in pregnant patients generating lack of working models. This in turn results into rejection of trials and can thus act as hindrance to the market growth.

Buy Complete Study at https://www.theinsightpartners.com/buy/TIPMD00002026?OP+sK

Contact us –
Phone : +1-646-491-9876
Email Id : sales@theinsightpartners.com
Website: https://www.theinsightpartners.com

About Us - The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

This release was published on openPR.